Six-Month Response to Delamanid Treatment in MDR TB Patients

Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Hewison, Cathy, Ferlazzo, Gabriella, Avaliani, Zaza, Hayrapetyan, Armen, Jonckheere, Sylvie, Khaidarkhanova, Zarema, Mohr, Erika, Sinha, Animesh, Skrahina, Alena, Vambe, Debrah, Vasilyeva, Irina, Lachenal, Nathalie, Varaine, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621551/
https://www.ncbi.nlm.nih.gov/pubmed/28767036
http://dx.doi.org/10.3201/eid2310.170468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621551/
https://www.ncbi.nlm.nih.gov/pubmed/28767036
http://dx.doi.org/10.3201/eid2310.170468

Ejemplares similares